Our findings highlight potential targets for future treatment of sarcopenia, necessitating further research to evaluate the feasibility of these five identified druggable genes (HP, HLA‐DRA, MAP 3K3, MFGE8, and COL15A1) as therapeutic drug targets for sarcopenia, especially for zinc supplementation and collagenase Clostridium histolyticum, which target for HP and COL15A1, respectively. The gene discussed is HLA-DRA; the disease is sarcopenia.